Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study

Osteoporosis International

Volumn 17, Issue 1, 2006, Pages 85-90

  Miller, Paul D ^a,e   Silverman, Stuart L ^b   Gold, Deborah T ^c   Taylor, Kathleen A ^d   Chen, Peiqi ^d   Wagman, Rachel B ^d  

^a Health Sciences Center and Colorado Center for Bone Research   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Anabolic drugs; DANCE; Nonvertebral fracture; Osteoporosis; Teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34];

ARTICLE; BACKACHE; BONE DENSITY; BONE MINERAL; CLINICAL OBSERVATION; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; FRACTURE; MEDICAL RESEARCH; METHODOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERTEBRA FRACTURE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COMMUNITY HEALTH SERVICES; EVIDENCE-BASED MEDICINE; FRACTURES, BONE; HUMANS; INFORMED CONSENT; OSTEOPOROSIS; PATIENT SELECTION; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RESEARCH DESIGN; TERIPARATIDE;

EID: 29144436283     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-1915-3     Document Type: Article

References (15)

1. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
2. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
3. Guyatt GH, Cranney A, Griffith L et al (2002) Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 31:659-679
4. Delmas PD, Recker RR, Chesnut CH 3rd et al (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15(10):792-798
5. Russell RG, Rogers MJ, Frith JC et al (1999) The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 14 [Suppl 2]:53-65
6. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645
7. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
8. Jiang Y, Zhao JJ, Mitlak BH et al (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941
9. Dempster DW, Cosman F, Kurland ES et al (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846-1853
10. Zanchetta JR, Bogado CE, Ferretti JL et al (2003) Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539-543
11. Paschalis EP, Burr DB, Mendelsohn R et al (2003) Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH(1-34) for 18 months. J Bone Miner Res 18:769-775
12. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17
13. Miller PD, Bilezikian JP, Deal C (2004) Clinical use of teriparatide in the real world: initial insights. Endocr Pract 10:139-148
14. Price DD, McGrath PA, Rafii A et al (1983) The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17:45-56
15. Bradburn NM (1969) The structure of psychological well-being. Aldine, Chicago